Novartis Ag (NVS) Cash from Financing Activities (2009 - 2026)

Novartis Ag has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$2.0 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 61.25% year-over-year to -$2.0 billion; the TTM figure through Jun 2026 stood at -$15.0 billion (up 7.23% YoY), while the FY2025 annual figure was -$14.9 billion, down 191.47% from the prior year.
• Cash from Financing Activities came in at -$2.0 billion for Q2 2026 at Novartis Ag, down from $3.6 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $11.0 billion in Q4 2023 to a low of -$13.8 billion in Q4 2025.
• Average Cash from Financing Activities over 5 years is -$2.5 billion, with a median of -$3.5 billion recorded in 2023.
• The largest YoY upside for Cash from Financing Activities was 366.41% in 2022 against a maximum downside of 206.78% in 2022.
• Over 5 years, Cash from Financing Activities stood at $8.7 billion in 2022, then grew by 27.23% to $11.0 billion in 2023, then sank by 175.91% to -$8.4 billion in 2024, then sank by 64.53% to -$13.8 billion in 2025, then jumped by 85.32% to -$2.0 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.0 billion in Q2 2026, $3.6 billion in Q1 2026, and -$13.8 billion in Q4 2025.